356 related articles for article (PubMed ID: 23313547)
1. Knock-down of the oxysterol receptor LXRα impairs cholesterol efflux in human primary macrophages: lack of compensation by LXRβ activation.
Ishibashi M; Filomenko R; Rébé C; Chevriaux A; Varin A; Derangère V; Bessède G; Gambert P; Lagrost L; Masson D
Biochem Pharmacol; 2013 Jul; 86(1):122-9. PubMed ID: 23313547
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol efflux is LXRα isoform-dependent in human macrophages.
Ma AZ; Song ZY; Zhang Q
BMC Cardiovasc Disord; 2014 Jul; 14():80. PubMed ID: 24996838
[TBL] [Abstract][Full Text] [Related]
3. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
[TBL] [Abstract][Full Text] [Related]
4. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
[TBL] [Abstract][Full Text] [Related]
5. Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells.
Tsui KH; Chung LC; Feng TH; Lee TY; Chang PL; Chen WT; Juang HH
Prostate; 2015 May; 75(6):603-15. PubMed ID: 25560459
[TBL] [Abstract][Full Text] [Related]
6. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms.
Morello F; Saglio E; Noghero A; Schiavone D; Williams TA; Verhovez A; Bussolino F; Veglio F; Mulatero P
Atherosclerosis; 2009 Nov; 207(1):38-44. PubMed ID: 19426978
[TBL] [Abstract][Full Text] [Related]
7. Macrophage-independent regulation of reverse cholesterol transport by liver X receptors.
Breevoort SR; Angdisen J; Schulman IG
Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1650-60. PubMed ID: 24947527
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel partial agonist of liver X receptor α (LXRα) via screening.
Li N; Wang X; Zhang J; Liu C; Li Y; Feng T; Xu Y; Si S
Biochem Pharmacol; 2014 Dec; 92(3):438-47. PubMed ID: 25450668
[TBL] [Abstract][Full Text] [Related]
9. Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2.
Noghero A; Perino A; Seano G; Saglio E; Lo Sasso G; Veglio F; Primo L; Hirsch E; Bussolino F; Morello F
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2280-8. PubMed ID: 22723445
[TBL] [Abstract][Full Text] [Related]
10. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice.
Zhang Y; Breevoort SR; Angdisen J; Fu M; Schmidt DR; Holmstrom SR; Kliewer SA; Mangelsdorf DJ; Schulman IG
J Clin Invest; 2012 May; 122(5):1688-99. PubMed ID: 22484817
[TBL] [Abstract][Full Text] [Related]
11. LXR agonism improves TNF-α-induced endothelial dysfunction in the absence of its cholesterol-modulating effects.
Spillmann F; Van Linthout S; Miteva K; Lorenz M; Stangl V; Schultheiss HP; Tschöpe C
Atherosclerosis; 2014 Jan; 232(1):1-9. PubMed ID: 24401210
[TBL] [Abstract][Full Text] [Related]
12. miR-206 controls LXRα expression and promotes LXR-mediated cholesterol efflux in macrophages.
Vinod M; Chennamsetty I; Colin S; Belloy L; De Paoli F; Schaider H; Graier WF; Frank S; Kratky D; Staels B; Chinetti-Gbaguidi G; Kostner GM
Biochim Biophys Acta; 2014 Jun; 1841(6):827-35. PubMed ID: 24603323
[TBL] [Abstract][Full Text] [Related]
13. Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages.
Shridas P; Bailey WM; Gizard F; Oslund RC; Gelb MH; Bruemmer D; Webb NR
Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):2014-21. PubMed ID: 20844270
[TBL] [Abstract][Full Text] [Related]
14. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
[TBL] [Abstract][Full Text] [Related]
15. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.
Quinet EM; Savio DA; Halpern AR; Chen L; Schuster GU; Gustafsson JA; Basso MD; Nambi P
Mol Pharmacol; 2006 Oct; 70(4):1340-9. PubMed ID: 16825483
[TBL] [Abstract][Full Text] [Related]
16. LXRalpha regulates human CETP expression in vitro and in transgenic mice.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Ubukata N; Terasaka N
Atherosclerosis; 2010 Sep; 212(1):139-45. PubMed ID: 20494359
[TBL] [Abstract][Full Text] [Related]
17. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes.
Laffitte BA; Repa JJ; Joseph SB; Wilpitz DC; Kast HR; Mangelsdorf DJ; Tontonoz P
Proc Natl Acad Sci U S A; 2001 Jan; 98(2):507-12. PubMed ID: 11149950
[TBL] [Abstract][Full Text] [Related]
18. Salvianolic acid B accelerated ABCA1-dependent cholesterol efflux by targeting PPAR-γ and LXRα.
Yue J; Li B; Jing Q; Guan Q
Biochem Biophys Res Commun; 2015 Jul; 462(3):233-8. PubMed ID: 25956064
[TBL] [Abstract][Full Text] [Related]
19. Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages.
Beyer C; Huang J; Beer J; Zhang Y; Palumbo-Zerr K; Zerr P; Distler A; Dees C; Maier C; Munoz L; Krönke G; Uderhardt S; Distler O; Jones S; Rose-John S; Oravecz T; Schett G; Distler JH
Ann Rheum Dis; 2015 Jun; 74(6):1317-24. PubMed ID: 24618263
[TBL] [Abstract][Full Text] [Related]
20. Activation of LXRs using the synthetic agonist GW3965 represses the production of pro-inflammatory cytokines by murine mast cells.
Nunomura S; Okayama Y; Matsumoto K; Hashimoto N; Endo-Umeda K; Terui T; Makishima M; Ra C
Allergol Int; 2015 Sep; 64 Suppl():S11-7. PubMed ID: 26344074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]